BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...from 2010-15. The investor group also includes Solasta Ventures, a subsidiary of South Korean firm Aju IB Investment...
BioCentury | Oct 4, 2019
Emerging Company Profile

Arcellx debuts with $85M, tech for adapting CAR Ts

...cancers and move into non-oncology indications. The series B round was led by new investors Aju IB Investment...
...N/A Funds raised: About $119 million Investors: Novo Holdings A/S, SR One, NEA, Takeda Ventures, Aju IB Investment...
BioCentury | Jul 16, 2019
Financial News

How ophthalmic play Trefoil plans to deploy $28M series A

...new investors Access Biotechnology and FemHealth Ventures as well as existing investors Hatteras Venture Partners, Aju IB Investment...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

...Real Estate Equities, Lilly Ventures, Amgen Ventures, 6 Dimensions Capital, Pfizer Ventures, Bessemer Venture Partners, AJU IB Investment...
BioCentury | Nov 16, 2018
Financial News

Kymera raises $65M series B

...round with participation by fellow new investors MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, Aju IB Investment...
BioCentury | Nov 13, 2018
Financial News

Kymera raises $65M series B

...round with participation by fellow new investors MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, Aju IB Investment...
BioCentury | Nov 13, 2018
Finance

Kymera’s degradation toolbox

...round with participation by fellow new investors MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, Aju IB Investment...
BioCentury | Dec 20, 2017
Company News

Management tracks: Intellia, Spectrum

...Autoimmune company Apellis Pharmaceuticals Inc. (NASDAQ:APLS) hired Timothy Sullivan as CFO. He was partner at AJU IB Investment...
BioCentury | Sep 23, 2017
Emerging Company Profile

Selective suppression

...Venture Partners, Bay City Capital , Morningside Ventures, Omega Funds, EcoR1 Capital, Cormorant Asset Management, Aju IB Investment...
BioCentury | Jul 28, 2017
Financial News

Kezar raises $50M in series B

...and Bay City Capital also participated, as did existing investors EcoR1 Capital, Omega Funds and Aju IB Investment...
Items per page:
1 - 10 of 30
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...from 2010-15. The investor group also includes Solasta Ventures, a subsidiary of South Korean firm Aju IB Investment...
BioCentury | Oct 4, 2019
Emerging Company Profile

Arcellx debuts with $85M, tech for adapting CAR Ts

...cancers and move into non-oncology indications. The series B round was led by new investors Aju IB Investment...
...N/A Funds raised: About $119 million Investors: Novo Holdings A/S, SR One, NEA, Takeda Ventures, Aju IB Investment...
BioCentury | Jul 16, 2019
Financial News

How ophthalmic play Trefoil plans to deploy $28M series A

...new investors Access Biotechnology and FemHealth Ventures as well as existing investors Hatteras Venture Partners, Aju IB Investment...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

...Real Estate Equities, Lilly Ventures, Amgen Ventures, 6 Dimensions Capital, Pfizer Ventures, Bessemer Venture Partners, AJU IB Investment...
BioCentury | Nov 16, 2018
Financial News

Kymera raises $65M series B

...round with participation by fellow new investors MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, Aju IB Investment...
BioCentury | Nov 13, 2018
Financial News

Kymera raises $65M series B

...round with participation by fellow new investors MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, Aju IB Investment...
BioCentury | Nov 13, 2018
Finance

Kymera’s degradation toolbox

...round with participation by fellow new investors MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, Aju IB Investment...
BioCentury | Dec 20, 2017
Company News

Management tracks: Intellia, Spectrum

...Autoimmune company Apellis Pharmaceuticals Inc. (NASDAQ:APLS) hired Timothy Sullivan as CFO. He was partner at AJU IB Investment...
BioCentury | Sep 23, 2017
Emerging Company Profile

Selective suppression

...Venture Partners, Bay City Capital , Morningside Ventures, Omega Funds, EcoR1 Capital, Cormorant Asset Management, Aju IB Investment...
BioCentury | Jul 28, 2017
Financial News

Kezar raises $50M in series B

...and Bay City Capital also participated, as did existing investors EcoR1 Capital, Omega Funds and Aju IB Investment...
Items per page:
1 - 10 of 30